Table 1.
Clinical characteristics of treatment groups (mean ± SD) n (%)
| Pantoprazole group(n = 52) | Somatostatin group(n = 49) | Total cohort(n = 101) | P value | |
| Sex (male) | 19 (36.5) | 13 (26.5) | 32 (31.7) | 0.280 |
| Age (yr) | 65.44 ± 19.46 | 64.24 ± 14.13 | 64.86 ± 17.01 | 0.735 |
| Hemodynamic shock | 26 (50.0) | 27 (55.1) | 53 (52.5) | 0.608 |
| Helicobacter pylori infection | 14 (26.9) | 8 (16.3) | 22 (21.8) | 0.197 |
| Hemoglobin (g/dL) | 8.56 ± 2.84 | 8.26 ± 2.61 | 8.41 ± 2.72 | 0.857 |
| Hemoglobin < 7 g/dL | 17 (32.7) | 16 (32.7) | 33 (32.7) | 0.997 |
| Blood urea nitrogen (mg/dL) | 40.20 ± 27.06 | 39.47 ± 26.83 | 39.84 ± 26.82 | 0.920 |
| Creatinine (mg/dL) | 1.17 ± 0.80 | 1.29 ± 1.33 | 1.23 ± 1.09 | 0.187 |
| Albumin (g/dL) | 3.12 ± 0.54 | 2.79 ± 0.59 | 2.96 ± 0.59 | 0.173 |
| Type 2 diabetes mellitus | 12 (23.1) | 16 (32.7) | 28 (27.7) | 0.283 |
| Hypertension | 22 (43.3) | 19 (38.8) | 41 (40.6) | 0.718 |
| Heart failure | 7 (13.5) | 4 (8.2) | 11 (10.9) | 0.393 |
| Ischemic heart disease | 15 (28.8) | 11 (22.4) | 26 (25.7) | 0.462 |
| Antiplatelet medication | 24 (46.2) | 20 (40.8) | 44 (43.6) | 0.589 |
| NSAID | 6 (11.5) | 3 (6.1) | 9 (8.9) | 0.340 |
| Multiple antiplatelet medications | 5 (9.6) | 2 (4.1) | 7 (6.9) | 0.274 |
| Steroids | 2 (3.8) | 4 (8.2) | 6 (5.9) | 0.359 |
| Melena | 31 (59.6) | 28 (57.1) | 59 (58.4) | 0.801 |
| Hematemesis | 28 (53.8) | 32 (65.3) | 60 (59.4) | 0.241 |
| Hematochezia | 2 (3.8) | 5 (10.2) | 7 (6.9) | 0.209 |
| Complete Rockall score | 6.84 ± 1.47 | 6.87 ± 1.31 | 6.86 ± 1.39 | 0.911 |
| Rockall score > 6 | 26 (50.0) | 29 (59.2) | 55 (54.5) | 0.354 |
| Early rebleeding | 6 (12.2) | 7 (14.3) | 13 (13.3) | 0.766 |
NSAID: Non-steroidal anti-inflammatory drug.